{"id":"W4406468796","doi":"10.1080/14796694.2024.2441107","title":"Open-label, phase Ia study of STING agonist BI 1703880 plus ezabenlimab for patients with advanced solid tumors","year":2025,"lang":"en","type":"article","venue":"Future Oncology","topic":"interferon and immune responses","field":"Immunology and Microbiology","cited_by":10,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"National Center for Advancing Translational Sciences; Eli Lilly Japan; Chugai Pharmaceutical; EMD Serono; Genentech; Sierra Oncology; Sun Pharma; Rakuten Medical; STCube; FibroGen; Astellas Pharma; Eisai; Regeneron Pharmaceuticals; Natera; Relay Therapeutics; Seagen; Actuate Therapeutics; BeiGene; Taiho Pharmaceutical; Kyowa Kirin Pharmaceutical Development; Pfizer; Incyte; Daiichi Sankyo Europe; Servier; Gilead Sciences; Japan Society for the Promotion of Science; GlaxoSmithKline; Mersana Therapeutics; Japan Agency for Medical Research and Development; Roivant Sciences; Amgen; AstraZeneca; Ono Pharmaceutical; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Agonist; Sting; Open label; Oncology; Internal medicine; Receptor; Clinical trial","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001164442,0.001383159,0.001830559,0.0004007971,0.0004885603,0.0009181144,0.0007228922,0.001132554,0.00572239],"category_scores_gemma":[0.0006352396,0.0005409345,0.0006549503,0.0003918486,0.0008933413,0.001128328,0.0002924328,0.002889985,0.001295938],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009278029,"about_ca_system_score_gemma":0.00175443,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009132395,"about_ca_topic_score_gemma":0.002994356,"domain_scores_codex":[0.9997246,0.0001069752,0.00001285852,0.00004868338,0.00002951451,0.00007732893],"domain_scores_gemma":[0.9995523,0.00005201199,0.00007675,0.00003851111,0.0000339619,0.0002464357],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7117044,0.1062448,0.003299388,0.00108333,0.0009424401,0.000251584,0.0003224147,0.002913063,0.04755944,0.0008920445,0.009373319,0.1154138],"study_design_scores_gemma":[0.5229012,0.4597771,0.004921932,0.00004517531,0.0001970896,0.0002087635,0.00008077685,0.001810727,0.003807666,0.0005108661,0.005711962,0.00002664693],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.977111,0.003126826,0.001703883,0.0008623717,0.0003899917,0.007508935,0.002536061,0.0003439791,0.00641706],"genre_scores_gemma":[0.977089,0.002002321,0.003247755,0.001237688,0.0002835036,0.005967509,0.002517644,0.00005142321,0.007603069],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00572239,"threshold_uncertainty_score":0.01914334,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01667253931178255,"score_gpt":0.3632815307260697,"score_spread":0.3466089914142871,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}